Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot3 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

• Narrative Content
• XML
• JSON
• TTL

: Participant Flow Report for NCT03421379

Raw json | Download

{
  "resourceType" : "Composition",
  "id" : "399871",
  "meta" : {
    "versionId" : "5",
    "lastUpdated" : "2025-12-11T20:35:21.032Z",
    "profile" : [
      🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-report"
    ]
  },
  "language" : "en",
  "text" : {
    "status" : "generated",
    "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\" xml:lang=\"en\" lang=\"en\"><p class=\"res-header-id\"><b>Generated Narrative: Composition 399871</b></p><a name=\"399871\"> </a><a name=\"hc399871\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">version: 5; Last updated: 2025-12-11 20:35:21+0000; Language: en</p><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-participant-flow-report.html\">ParticipantFlowReport</a></p></div><p><b>url</b>: <a href=\"https://fevir.net/resources/Composition/399871\">https://fevir.net/resources/Composition/399871</a></p><p><b>identifier</b>: FEvIR Object Identifier/399871, FEvIR Linking Identifier/NCT03421379-participant-flow-report</p><p><b>status</b>: Final</p><p><b>type</b>: <span title=\"Codes:{https://fevir.net/resources/CodeSystem/179423 ParticipantFlowReport}\">Participant Flow Report</span></p><p><b>date</b>: 2025-12-11 20:35:21+0000</p><p><b>author</b>: [No author listed.]</p><p><b>title</b>: Participant Flow Report for NCT03421379</p><p><b>custodian</b>: <a href=\"Organization-118079.html\">Computable Publishing LLC</a></p><h3>RelatesTos</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>Target[x]</b></td></tr><tr><td style=\"display: none\">*</td><td>Cite As</td><td><div><p>Participant Flow Report for NCT03421379 [Database Entry: FHIR Composition Resource]. Contributors: [No author listed.] [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 399871. Revised 2025-12-11. Available at: https://fevir.net/resources/Composition/399871. Computable resource at: https://fevir.net/resources/Composition/399871#json.</p>\n</div></td></tr></table><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Group #FG000</b></p><a name=\"399871/FG000\"> </a><a name=\"hc399871/FG000\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-exposure-group.html\">ExposureGroup</a></p></div><p><b>name</b>: NCT03421379 Flow Group Glucagon Nasal Powder/Glucagon Hydrochloride</p><p><b>description</b>: </p><div><p>A single dose of 3 milligram (mg) glucagon nasal powder was administered intranasally in period 1 then 1 mg single dose intramuscular glucagon hydrochloride solution was administered in period 2.</p>\n</div><p><b>type</b>: Person</p><p><b>membership</b>: Enumerated</p><h3>Characteristics</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Code</b></td><td><b>Value[x]</b></td><td><b>Exclude</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">Research Study from which this is a flow group</span></td><td>NCT03421379</td><td>false</td></tr></table></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Group #FG001</b></p><a name=\"399871/FG001\"> </a><a name=\"hc399871/FG001\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-exposure-group.html\">ExposureGroup</a></p></div><p><b>name</b>: NCT03421379 Flow Group Glucagon Hydrochloride Solution/Glucagon Nasal Powder</p><p><b>description</b>: </p><div><p>A single dose of 1 mg glucagon hydrochloride solution was administered intramuscular (IM) in period 1 then 3 mg single dose glucagon nasal powder was administered in period 2.</p>\n</div><p><b>type</b>: Person</p><p><b>membership</b>: Enumerated</p><h3>Characteristics</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Code</b></td><td><b>Value[x]</b></td><td><b>Exclude</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">Research Study from which this is a flow group</span></td><td>NCT03421379</td><td>false</td></tr></table></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-flow-milestone-0-Period-1-group-FG000</b></p><a name=\"399871/NCT03421379-flow-milestone-0-Period-1-group-FG000\"> </a><a name=\"hc399871/NCT03421379-flow-milestone-0-Period-1-group-FG000\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-participant-flow-evidence.html\">ParticipantFlowEvidence</a></p></div><p><b>identifier</b>: FEvIR Linking Identifier/NCT03421379-flow-milestone-0-Period-1-group-FG000</p><p><b>title</b>: ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - STARTED at Period 1</p><p><b>status</b>: Active</p><p><b>author</b>: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter: </p><h3>UseContexts</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Code</b></td><td><b>Value[x]</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"CodeSystem-179423.html#179423-evidence-communication\">Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication</a> (Evidence Communication)</td><td><span title=\"Codes:{https://fevir.net/resources/CodeSystem/179423 ParticipantFlowEvidence}\">ParticipantFlowEvidence</span></td></tr></table><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Population</p><p><b>observed</b>: <a href=\"#hc399871/FG000\">Glucagon Nasal Powder/Glucagon Hydrochloride</a></p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: STARTED at Period 1</p></blockquote><h3>Statistics</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>StatisticType</b></td><td><b>Quantity</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{https://fevir.net/sevco STATO:0000047}\">Count</span></td><td>34</td></tr></table></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-flow-milestone-0-Period-1-group-FG001</b></p><a name=\"399871/NCT03421379-flow-milestone-0-Period-1-group-FG001\"> </a><a name=\"hc399871/NCT03421379-flow-milestone-0-Period-1-group-FG001\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-participant-flow-evidence.html\">ParticipantFlowEvidence</a></p></div><p><b>identifier</b>: FEvIR Linking Identifier/NCT03421379-flow-milestone-0-Period-1-group-FG001</p><p><b>title</b>: ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - STARTED at Period 1</p><p><b>status</b>: Active</p><p><b>author</b>: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter: </p><h3>UseContexts</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Code</b></td><td><b>Value[x]</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"CodeSystem-179423.html#179423-evidence-communication\">Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication</a> (Evidence Communication)</td><td><span title=\"Codes:{https://fevir.net/resources/CodeSystem/179423 ParticipantFlowEvidence}\">ParticipantFlowEvidence</span></td></tr></table><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Population</p><p><b>observed</b>: <a href=\"#hc399871/FG001\">Glucagon Hydrochloride Solution/Glucagon Nasal Powder</a></p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: STARTED at Period 1</p></blockquote><h3>Statistics</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>StatisticType</b></td><td><b>Quantity</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{https://fevir.net/sevco STATO:0000047}\">Count</span></td><td>41</td></tr></table></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-flow-milestone-1-Period-1-group-FG000</b></p><a name=\"399871/NCT03421379-flow-milestone-1-Period-1-group-FG000\"> </a><a name=\"hc399871/NCT03421379-flow-milestone-1-Period-1-group-FG000\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-participant-flow-evidence.html\">ParticipantFlowEvidence</a></p></div><p><b>identifier</b>: FEvIR Linking Identifier/NCT03421379-flow-milestone-1-Period-1-group-FG000</p><p><b>title</b>: ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - Received at Least One Dose of Study Drug at Period 1</p><p><b>status</b>: Active</p><p><b>author</b>: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter: </p><h3>UseContexts</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Code</b></td><td><b>Value[x]</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"CodeSystem-179423.html#179423-evidence-communication\">Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication</a> (Evidence Communication)</td><td><span title=\"Codes:{https://fevir.net/resources/CodeSystem/179423 ParticipantFlowEvidence}\">ParticipantFlowEvidence</span></td></tr></table><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Population</p><p><b>observed</b>: <a href=\"#hc399871/FG000\">Glucagon Nasal Powder/Glucagon Hydrochloride</a></p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: Received at Least One Dose of Study Drug at Period 1</p></blockquote><h3>Statistics</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>StatisticType</b></td><td><b>Quantity</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{https://fevir.net/sevco STATO:0000047}\">Count</span></td><td>33</td></tr></table></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-flow-milestone-1-Period-1-group-FG001</b></p><a name=\"399871/NCT03421379-flow-milestone-1-Period-1-group-FG001\"> </a><a name=\"hc399871/NCT03421379-flow-milestone-1-Period-1-group-FG001\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-participant-flow-evidence.html\">ParticipantFlowEvidence</a></p></div><p><b>identifier</b>: FEvIR Linking Identifier/NCT03421379-flow-milestone-1-Period-1-group-FG001</p><p><b>title</b>: ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - Received at Least One Dose of Study Drug at Period 1</p><p><b>status</b>: Active</p><p><b>author</b>: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter: </p><h3>UseContexts</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Code</b></td><td><b>Value[x]</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"CodeSystem-179423.html#179423-evidence-communication\">Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication</a> (Evidence Communication)</td><td><span title=\"Codes:{https://fevir.net/resources/CodeSystem/179423 ParticipantFlowEvidence}\">ParticipantFlowEvidence</span></td></tr></table><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Population</p><p><b>observed</b>: <a href=\"#hc399871/FG001\">Glucagon Hydrochloride Solution/Glucagon Nasal Powder</a></p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: Received at Least One Dose of Study Drug at Period 1</p></blockquote><h3>Statistics</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>StatisticType</b></td><td><b>Quantity</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{https://fevir.net/sevco STATO:0000047}\">Count</span></td><td>39</td></tr></table></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-flow-milestone-2-Period-1-group-FG000</b></p><a name=\"399871/NCT03421379-flow-milestone-2-Period-1-group-FG000\"> </a><a name=\"hc399871/NCT03421379-flow-milestone-2-Period-1-group-FG000\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-participant-flow-evidence.html\">ParticipantFlowEvidence</a></p></div><p><b>identifier</b>: FEvIR Linking Identifier/NCT03421379-flow-milestone-2-Period-1-group-FG000</p><p><b>title</b>: ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - COMPLETED at Period 1</p><p><b>status</b>: Active</p><p><b>author</b>: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter: </p><h3>UseContexts</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Code</b></td><td><b>Value[x]</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"CodeSystem-179423.html#179423-evidence-communication\">Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication</a> (Evidence Communication)</td><td><span title=\"Codes:{https://fevir.net/resources/CodeSystem/179423 ParticipantFlowEvidence}\">ParticipantFlowEvidence</span></td></tr></table><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Population</p><p><b>observed</b>: <a href=\"#hc399871/FG000\">Glucagon Nasal Powder/Glucagon Hydrochloride</a></p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: COMPLETED at Period 1</p></blockquote><h3>Statistics</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>StatisticType</b></td><td><b>Quantity</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{https://fevir.net/sevco STATO:0000047}\">Count</span></td><td>32</td></tr></table></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-flow-milestone-2-Period-1-group-FG001</b></p><a name=\"399871/NCT03421379-flow-milestone-2-Period-1-group-FG001\"> </a><a name=\"hc399871/NCT03421379-flow-milestone-2-Period-1-group-FG001\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-participant-flow-evidence.html\">ParticipantFlowEvidence</a></p></div><p><b>identifier</b>: FEvIR Linking Identifier/NCT03421379-flow-milestone-2-Period-1-group-FG001</p><p><b>title</b>: ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - COMPLETED at Period 1</p><p><b>status</b>: Active</p><p><b>author</b>: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter: </p><h3>UseContexts</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Code</b></td><td><b>Value[x]</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"CodeSystem-179423.html#179423-evidence-communication\">Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication</a> (Evidence Communication)</td><td><span title=\"Codes:{https://fevir.net/resources/CodeSystem/179423 ParticipantFlowEvidence}\">ParticipantFlowEvidence</span></td></tr></table><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Population</p><p><b>observed</b>: <a href=\"#hc399871/FG001\">Glucagon Hydrochloride Solution/Glucagon Nasal Powder</a></p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: COMPLETED at Period 1</p></blockquote><h3>Statistics</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>StatisticType</b></td><td><b>Quantity</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{https://fevir.net/sevco STATO:0000047}\">Count</span></td><td>37</td></tr></table></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-flow-milestone-3-Period-1-group-FG000</b></p><a name=\"399871/NCT03421379-flow-milestone-3-Period-1-group-FG000\"> </a><a name=\"hc399871/NCT03421379-flow-milestone-3-Period-1-group-FG000\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-participant-flow-evidence.html\">ParticipantFlowEvidence</a></p></div><p><b>identifier</b>: FEvIR Linking Identifier/NCT03421379-flow-milestone-3-Period-1-group-FG000</p><p><b>title</b>: ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - NOT COMPLETED at Period 1</p><p><b>status</b>: Active</p><p><b>author</b>: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter: </p><h3>UseContexts</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Code</b></td><td><b>Value[x]</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"CodeSystem-179423.html#179423-evidence-communication\">Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication</a> (Evidence Communication)</td><td><span title=\"Codes:{https://fevir.net/resources/CodeSystem/179423 ParticipantFlowEvidence}\">ParticipantFlowEvidence</span></td></tr></table><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Population</p><p><b>observed</b>: <a href=\"#hc399871/FG000\">Glucagon Nasal Powder/Glucagon Hydrochloride</a></p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: NOT COMPLETED at Period 1</p></blockquote><h3>Statistics</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>StatisticType</b></td><td><b>Quantity</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{https://fevir.net/sevco STATO:0000047}\">Count</span></td><td>2</td></tr></table></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-flow-milestone-3-Period-1-group-FG001</b></p><a name=\"399871/NCT03421379-flow-milestone-3-Period-1-group-FG001\"> </a><a name=\"hc399871/NCT03421379-flow-milestone-3-Period-1-group-FG001\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-participant-flow-evidence.html\">ParticipantFlowEvidence</a></p></div><p><b>identifier</b>: FEvIR Linking Identifier/NCT03421379-flow-milestone-3-Period-1-group-FG001</p><p><b>title</b>: ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - NOT COMPLETED at Period 1</p><p><b>status</b>: Active</p><p><b>author</b>: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter: </p><h3>UseContexts</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Code</b></td><td><b>Value[x]</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"CodeSystem-179423.html#179423-evidence-communication\">Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication</a> (Evidence Communication)</td><td><span title=\"Codes:{https://fevir.net/resources/CodeSystem/179423 ParticipantFlowEvidence}\">ParticipantFlowEvidence</span></td></tr></table><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Population</p><p><b>observed</b>: <a href=\"#hc399871/FG001\">Glucagon Hydrochloride Solution/Glucagon Nasal Powder</a></p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: NOT COMPLETED at Period 1</p></blockquote><h3>Statistics</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>StatisticType</b></td><td><b>Quantity</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{https://fevir.net/sevco STATO:0000047}\">Count</span></td><td>4</td></tr></table></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-flow-reason-Period-1-group-FG000</b></p><a name=\"399871/NCT03421379-flow-reason-Period-1-group-FG000\"> </a><a name=\"hc399871/NCT03421379-flow-reason-Period-1-group-FG000\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-participant-flow-evidence.html\">ParticipantFlowEvidence</a></p></div><p><b>identifier</b>: FEvIR Linking Identifier/NCT03421379-flow-reason-Period-1-group-FG000</p><p><b>title</b>: ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - Reasons for withdraw at Period 1</p><p><b>status</b>: Active</p><p><b>author</b>: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter: </p><h3>UseContexts</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Code</b></td><td><b>Value[x]</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"CodeSystem-179423.html#179423-evidence-communication\">Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication</a> (Evidence Communication)</td><td><span title=\"Codes:{https://fevir.net/resources/CodeSystem/179423 ParticipantFlowEvidence}\">ParticipantFlowEvidence</span></td></tr></table><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Population</p><p><b>observed</b>: <a href=\"#hc399871/FG000\">Glucagon Nasal Powder/Glucagon Hydrochloride</a></p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: Reasons for withdraw at Period 1</p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:{https://fevir.net/sevco STATO:0000047}\">Count</span></p><p><b>category</b>: <span title=\"Codes:\">Withdrawal by Subject</span></p><p><b>quantity</b>: 0</p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:{https://fevir.net/sevco STATO:0000047}\">Count</span></p><p><b>category</b>: <span title=\"Codes:\">Physician Decision</span></p><p><b>quantity</b>: 1</p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:{https://fevir.net/sevco STATO:0000047}\">Count</span></p><p><b>category</b>: <span title=\"Codes:\">Did not receive treatment</span></p><p><b>quantity</b>: 1</p></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-flow-reason-Period-1-group-FG001</b></p><a name=\"399871/NCT03421379-flow-reason-Period-1-group-FG001\"> </a><a name=\"hc399871/NCT03421379-flow-reason-Period-1-group-FG001\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-participant-flow-evidence.html\">ParticipantFlowEvidence</a></p></div><p><b>identifier</b>: FEvIR Linking Identifier/NCT03421379-flow-reason-Period-1-group-FG001</p><p><b>title</b>: ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - Reasons for withdraw at Period 1</p><p><b>status</b>: Active</p><p><b>author</b>: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter: </p><h3>UseContexts</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Code</b></td><td><b>Value[x]</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"CodeSystem-179423.html#179423-evidence-communication\">Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication</a> (Evidence Communication)</td><td><span title=\"Codes:{https://fevir.net/resources/CodeSystem/179423 ParticipantFlowEvidence}\">ParticipantFlowEvidence</span></td></tr></table><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Population</p><p><b>observed</b>: <a href=\"#hc399871/FG001\">Glucagon Hydrochloride Solution/Glucagon Nasal Powder</a></p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: Reasons for withdraw at Period 1</p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:{https://fevir.net/sevco STATO:0000047}\">Count</span></p><p><b>category</b>: <span title=\"Codes:\">Withdrawal by Subject</span></p><p><b>quantity</b>: 1</p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:{https://fevir.net/sevco STATO:0000047}\">Count</span></p><p><b>category</b>: <span title=\"Codes:\">Physician Decision</span></p><p><b>quantity</b>: 1</p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:{https://fevir.net/sevco STATO:0000047}\">Count</span></p><p><b>category</b>: <span title=\"Codes:\">Did not receive treatment</span></p><p><b>quantity</b>: 2</p></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-flow-milestone-0-Washout-Period--OPEN---3-to-1-FG000</b></p><a name=\"399871/NCT03421379-flow-milestone-0-Washout-Period--OPEN---3-to-1-FG000\"> </a><a name=\"hc399871/NCT03421379-flow-milestone-0-Washout-Period--OPEN---3-to-1-FG000\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-participant-flow-evidence.html\">ParticipantFlowEvidence</a></p></div><p><b>identifier</b>: FEvIR Linking Identifier/NCT03421379-flow-milestone-0-Washout-Period--OPEN---3-to-1-FG000</p><p><b>title</b>: ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - STARTED at Washout Period (3 to 14 Days)</p><p><b>status</b>: Active</p><p><b>author</b>: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter: </p><h3>UseContexts</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Code</b></td><td><b>Value[x]</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"CodeSystem-179423.html#179423-evidence-communication\">Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication</a> (Evidence Communication)</td><td><span title=\"Codes:{https://fevir.net/resources/CodeSystem/179423 ParticipantFlowEvidence}\">ParticipantFlowEvidence</span></td></tr></table><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Population</p><p><b>observed</b>: <a href=\"#hc399871/FG000\">Glucagon Nasal Powder/Glucagon Hydrochloride</a></p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: STARTED at Washout Period (3 to 14 Days)</p></blockquote><h3>Statistics</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>StatisticType</b></td><td><b>Quantity</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{https://fevir.net/sevco STATO:0000047}\">Count</span></td><td>32</td></tr></table></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-flow-milestone-0-Washout-Period--OPEN---3-to-1-FG001</b></p><a name=\"399871/NCT03421379-flow-milestone-0-Washout-Period--OPEN---3-to-1-FG001\"> </a><a name=\"hc399871/NCT03421379-flow-milestone-0-Washout-Period--OPEN---3-to-1-FG001\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-participant-flow-evidence.html\">ParticipantFlowEvidence</a></p></div><p><b>identifier</b>: FEvIR Linking Identifier/NCT03421379-flow-milestone-0-Washout-Period--OPEN---3-to-1-FG001</p><p><b>title</b>: ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - STARTED at Washout Period (3 to 14 Days)</p><p><b>status</b>: Active</p><p><b>author</b>: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter: </p><h3>UseContexts</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Code</b></td><td><b>Value[x]</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"CodeSystem-179423.html#179423-evidence-communication\">Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication</a> (Evidence Communication)</td><td><span title=\"Codes:{https://fevir.net/resources/CodeSystem/179423 ParticipantFlowEvidence}\">ParticipantFlowEvidence</span></td></tr></table><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Population</p><p><b>observed</b>: <a href=\"#hc399871/FG001\">Glucagon Hydrochloride Solution/Glucagon Nasal Powder</a></p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: STARTED at Washout Period (3 to 14 Days)</p></blockquote><h3>Statistics</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>StatisticType</b></td><td><b>Quantity</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{https://fevir.net/sevco STATO:0000047}\">Count</span></td><td>37</td></tr></table></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-flow-milestone-1-Washout-Period--OPEN---3-to-1-FG000</b></p><a name=\"399871/NCT03421379-flow-milestone-1-Washout-Period--OPEN---3-to-1-FG000\"> </a><a name=\"hc399871/NCT03421379-flow-milestone-1-Washout-Period--OPEN---3-to-1-FG000\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-participant-flow-evidence.html\">ParticipantFlowEvidence</a></p></div><p><b>identifier</b>: FEvIR Linking Identifier/NCT03421379-flow-milestone-1-Washout-Period--OPEN---3-to-1-FG000</p><p><b>title</b>: ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - COMPLETED at Washout Period (3 to 14 Days)</p><p><b>status</b>: Active</p><p><b>author</b>: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter: </p><h3>UseContexts</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Code</b></td><td><b>Value[x]</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"CodeSystem-179423.html#179423-evidence-communication\">Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication</a> (Evidence Communication)</td><td><span title=\"Codes:{https://fevir.net/resources/CodeSystem/179423 ParticipantFlowEvidence}\">ParticipantFlowEvidence</span></td></tr></table><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Population</p><p><b>observed</b>: <a href=\"#hc399871/FG000\">Glucagon Nasal Powder/Glucagon Hydrochloride</a></p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: COMPLETED at Washout Period (3 to 14 Days)</p></blockquote><h3>Statistics</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>StatisticType</b></td><td><b>Quantity</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{https://fevir.net/sevco STATO:0000047}\">Count</span></td><td>32</td></tr></table></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-flow-milestone-1-Washout-Period--OPEN---3-to-1-FG001</b></p><a name=\"399871/NCT03421379-flow-milestone-1-Washout-Period--OPEN---3-to-1-FG001\"> </a><a name=\"hc399871/NCT03421379-flow-milestone-1-Washout-Period--OPEN---3-to-1-FG001\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-participant-flow-evidence.html\">ParticipantFlowEvidence</a></p></div><p><b>identifier</b>: FEvIR Linking Identifier/NCT03421379-flow-milestone-1-Washout-Period--OPEN---3-to-1-FG001</p><p><b>title</b>: ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - COMPLETED at Washout Period (3 to 14 Days)</p><p><b>status</b>: Active</p><p><b>author</b>: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter: </p><h3>UseContexts</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Code</b></td><td><b>Value[x]</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"CodeSystem-179423.html#179423-evidence-communication\">Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication</a> (Evidence Communication)</td><td><span title=\"Codes:{https://fevir.net/resources/CodeSystem/179423 ParticipantFlowEvidence}\">ParticipantFlowEvidence</span></td></tr></table><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Population</p><p><b>observed</b>: <a href=\"#hc399871/FG001\">Glucagon Hydrochloride Solution/Glucagon Nasal Powder</a></p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: COMPLETED at Washout Period (3 to 14 Days)</p></blockquote><h3>Statistics</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>StatisticType</b></td><td><b>Quantity</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{https://fevir.net/sevco STATO:0000047}\">Count</span></td><td>37</td></tr></table></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-flow-milestone-2-Washout-Period--OPEN---3-to-1-FG000</b></p><a name=\"399871/NCT03421379-flow-milestone-2-Washout-Period--OPEN---3-to-1-FG000\"> </a><a name=\"hc399871/NCT03421379-flow-milestone-2-Washout-Period--OPEN---3-to-1-FG000\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-participant-flow-evidence.html\">ParticipantFlowEvidence</a></p></div><p><b>identifier</b>: FEvIR Linking Identifier/NCT03421379-flow-milestone-2-Washout-Period--OPEN---3-to-1-FG000</p><p><b>title</b>: ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - NOT COMPLETED at Washout Period (3 to 14 Days)</p><p><b>status</b>: Active</p><p><b>author</b>: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter: </p><h3>UseContexts</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Code</b></td><td><b>Value[x]</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"CodeSystem-179423.html#179423-evidence-communication\">Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication</a> (Evidence Communication)</td><td><span title=\"Codes:{https://fevir.net/resources/CodeSystem/179423 ParticipantFlowEvidence}\">ParticipantFlowEvidence</span></td></tr></table><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Population</p><p><b>observed</b>: <a href=\"#hc399871/FG000\">Glucagon Nasal Powder/Glucagon Hydrochloride</a></p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: NOT COMPLETED at Washout Period (3 to 14 Days)</p></blockquote><h3>Statistics</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>StatisticType</b></td><td><b>Quantity</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{https://fevir.net/sevco STATO:0000047}\">Count</span></td><td>0</td></tr></table></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-flow-milestone-2-Washout-Period--OPEN---3-to-1-FG001</b></p><a name=\"399871/NCT03421379-flow-milestone-2-Washout-Period--OPEN---3-to-1-FG001\"> </a><a name=\"hc399871/NCT03421379-flow-milestone-2-Washout-Period--OPEN---3-to-1-FG001\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-participant-flow-evidence.html\">ParticipantFlowEvidence</a></p></div><p><b>identifier</b>: FEvIR Linking Identifier/NCT03421379-flow-milestone-2-Washout-Period--OPEN---3-to-1-FG001</p><p><b>title</b>: ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - NOT COMPLETED at Washout Period (3 to 14 Days)</p><p><b>status</b>: Active</p><p><b>author</b>: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter: </p><h3>UseContexts</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Code</b></td><td><b>Value[x]</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"CodeSystem-179423.html#179423-evidence-communication\">Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication</a> (Evidence Communication)</td><td><span title=\"Codes:{https://fevir.net/resources/CodeSystem/179423 ParticipantFlowEvidence}\">ParticipantFlowEvidence</span></td></tr></table><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Population</p><p><b>observed</b>: <a href=\"#hc399871/FG001\">Glucagon Hydrochloride Solution/Glucagon Nasal Powder</a></p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: NOT COMPLETED at Washout Period (3 to 14 Days)</p></blockquote><h3>Statistics</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>StatisticType</b></td><td><b>Quantity</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{https://fevir.net/sevco STATO:0000047}\">Count</span></td><td>0</td></tr></table></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-flow-milestone-0-Period-2-group-FG000</b></p><a name=\"399871/NCT03421379-flow-milestone-0-Period-2-group-FG000\"> </a><a name=\"hc399871/NCT03421379-flow-milestone-0-Period-2-group-FG000\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-participant-flow-evidence.html\">ParticipantFlowEvidence</a></p></div><p><b>identifier</b>: FEvIR Linking Identifier/NCT03421379-flow-milestone-0-Period-2-group-FG000</p><p><b>title</b>: ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - STARTED at Period 2</p><p><b>status</b>: Active</p><p><b>author</b>: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter: </p><h3>UseContexts</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Code</b></td><td><b>Value[x]</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"CodeSystem-179423.html#179423-evidence-communication\">Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication</a> (Evidence Communication)</td><td><span title=\"Codes:{https://fevir.net/resources/CodeSystem/179423 ParticipantFlowEvidence}\">ParticipantFlowEvidence</span></td></tr></table><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Population</p><p><b>observed</b>: <a href=\"#hc399871/FG000\">Glucagon Nasal Powder/Glucagon Hydrochloride</a></p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: STARTED at Period 2</p></blockquote><h3>Statistics</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>StatisticType</b></td><td><b>Quantity</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{https://fevir.net/sevco STATO:0000047}\">Count</span></td><td>32</td></tr></table></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-flow-milestone-0-Period-2-group-FG001</b></p><a name=\"399871/NCT03421379-flow-milestone-0-Period-2-group-FG001\"> </a><a name=\"hc399871/NCT03421379-flow-milestone-0-Period-2-group-FG001\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-participant-flow-evidence.html\">ParticipantFlowEvidence</a></p></div><p><b>identifier</b>: FEvIR Linking Identifier/NCT03421379-flow-milestone-0-Period-2-group-FG001</p><p><b>title</b>: ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - STARTED at Period 2</p><p><b>status</b>: Active</p><p><b>author</b>: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter: </p><h3>UseContexts</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Code</b></td><td><b>Value[x]</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"CodeSystem-179423.html#179423-evidence-communication\">Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication</a> (Evidence Communication)</td><td><span title=\"Codes:{https://fevir.net/resources/CodeSystem/179423 ParticipantFlowEvidence}\">ParticipantFlowEvidence</span></td></tr></table><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Population</p><p><b>observed</b>: <a href=\"#hc399871/FG001\">Glucagon Hydrochloride Solution/Glucagon Nasal Powder</a></p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: STARTED at Period 2</p></blockquote><h3>Statistics</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>StatisticType</b></td><td><b>Quantity</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{https://fevir.net/sevco STATO:0000047}\">Count</span></td><td>37</td></tr></table></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-flow-milestone-1-Period-2-group-FG000</b></p><a name=\"399871/NCT03421379-flow-milestone-1-Period-2-group-FG000\"> </a><a name=\"hc399871/NCT03421379-flow-milestone-1-Period-2-group-FG000\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-participant-flow-evidence.html\">ParticipantFlowEvidence</a></p></div><p><b>identifier</b>: FEvIR Linking Identifier/NCT03421379-flow-milestone-1-Period-2-group-FG000</p><p><b>title</b>: ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - COMPLETED at Period 2</p><p><b>status</b>: Active</p><p><b>author</b>: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter: </p><h3>UseContexts</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Code</b></td><td><b>Value[x]</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"CodeSystem-179423.html#179423-evidence-communication\">Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication</a> (Evidence Communication)</td><td><span title=\"Codes:{https://fevir.net/resources/CodeSystem/179423 ParticipantFlowEvidence}\">ParticipantFlowEvidence</span></td></tr></table><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Population</p><p><b>observed</b>: <a href=\"#hc399871/FG000\">Glucagon Nasal Powder/Glucagon Hydrochloride</a></p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: COMPLETED at Period 2</p></blockquote><h3>Statistics</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>StatisticType</b></td><td><b>Quantity</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{https://fevir.net/sevco STATO:0000047}\">Count</span></td><td>32</td></tr></table></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-flow-milestone-1-Period-2-group-FG001</b></p><a name=\"399871/NCT03421379-flow-milestone-1-Period-2-group-FG001\"> </a><a name=\"hc399871/NCT03421379-flow-milestone-1-Period-2-group-FG001\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-participant-flow-evidence.html\">ParticipantFlowEvidence</a></p></div><p><b>identifier</b>: FEvIR Linking Identifier/NCT03421379-flow-milestone-1-Period-2-group-FG001</p><p><b>title</b>: ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - COMPLETED at Period 2</p><p><b>status</b>: Active</p><p><b>author</b>: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter: </p><h3>UseContexts</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Code</b></td><td><b>Value[x]</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"CodeSystem-179423.html#179423-evidence-communication\">Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication</a> (Evidence Communication)</td><td><span title=\"Codes:{https://fevir.net/resources/CodeSystem/179423 ParticipantFlowEvidence}\">ParticipantFlowEvidence</span></td></tr></table><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Population</p><p><b>observed</b>: <a href=\"#hc399871/FG001\">Glucagon Hydrochloride Solution/Glucagon Nasal Powder</a></p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: COMPLETED at Period 2</p></blockquote><h3>Statistics</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>StatisticType</b></td><td><b>Quantity</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{https://fevir.net/sevco STATO:0000047}\">Count</span></td><td>37</td></tr></table></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-flow-milestone-2-Period-2-group-FG000</b></p><a name=\"399871/NCT03421379-flow-milestone-2-Period-2-group-FG000\"> </a><a name=\"hc399871/NCT03421379-flow-milestone-2-Period-2-group-FG000\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-participant-flow-evidence.html\">ParticipantFlowEvidence</a></p></div><p><b>identifier</b>: FEvIR Linking Identifier/NCT03421379-flow-milestone-2-Period-2-group-FG000</p><p><b>title</b>: ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - NOT COMPLETED at Period 2</p><p><b>status</b>: Active</p><p><b>author</b>: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter: </p><h3>UseContexts</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Code</b></td><td><b>Value[x]</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"CodeSystem-179423.html#179423-evidence-communication\">Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication</a> (Evidence Communication)</td><td><span title=\"Codes:{https://fevir.net/resources/CodeSystem/179423 ParticipantFlowEvidence}\">ParticipantFlowEvidence</span></td></tr></table><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Population</p><p><b>observed</b>: <a href=\"#hc399871/FG000\">Glucagon Nasal Powder/Glucagon Hydrochloride</a></p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: NOT COMPLETED at Period 2</p></blockquote><h3>Statistics</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>StatisticType</b></td><td><b>Quantity</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{https://fevir.net/sevco STATO:0000047}\">Count</span></td><td>0</td></tr></table></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-flow-milestone-2-Period-2-group-FG001</b></p><a name=\"399871/NCT03421379-flow-milestone-2-Period-2-group-FG001\"> </a><a name=\"hc399871/NCT03421379-flow-milestone-2-Period-2-group-FG001\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-participant-flow-evidence.html\">ParticipantFlowEvidence</a></p></div><p><b>identifier</b>: FEvIR Linking Identifier/NCT03421379-flow-milestone-2-Period-2-group-FG001</p><p><b>title</b>: ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - NOT COMPLETED at Period 2</p><p><b>status</b>: Active</p><p><b>author</b>: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter: </p><h3>UseContexts</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Code</b></td><td><b>Value[x]</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"CodeSystem-179423.html#179423-evidence-communication\">Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication</a> (Evidence Communication)</td><td><span title=\"Codes:{https://fevir.net/resources/CodeSystem/179423 ParticipantFlowEvidence}\">ParticipantFlowEvidence</span></td></tr></table><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Population</p><p><b>observed</b>: <a href=\"#hc399871/FG001\">Glucagon Hydrochloride Solution/Glucagon Nasal Powder</a></p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: NOT COMPLETED at Period 2</p></blockquote><h3>Statistics</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>StatisticType</b></td><td><b>Quantity</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{https://fevir.net/sevco STATO:0000047}\">Count</span></td><td>0</td></tr></table></blockquote></div>"
  },
  "contained" : [
    {
      "resourceType" : "Group",
      "id" : "FG000",
      "meta" : {
        "profile" : [
          🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/exposure-group"
        ]
      },
      "name" : "NCT03421379 Flow Group Glucagon Nasal Powder/Glucagon Hydrochloride",
      "description" : "A single dose of 3 milligram (mg) glucagon nasal powder was administered intranasally in period 1 then 1 mg single dose intramuscular glucagon hydrochloride solution was administered in period 2.",
      "type" : "person",
      "membership" : "enumerated",
      "characteristic" : [
        {
          "code" : {
            "text" : "Research Study from which this is a flow group"
          },
          "valueReference" : {
            "display" : "NCT03421379"
          },
          "exclude" : false
        }
      ]
    },
    {
      "resourceType" : "Group",
      "id" : "FG001",
      "meta" : {
        "profile" : [
          🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/exposure-group"
        ]
      },
      "name" : "NCT03421379 Flow Group Glucagon Hydrochloride Solution/Glucagon Nasal Powder",
      "description" : "A single dose of 1 mg glucagon hydrochloride solution was administered intramuscular (IM) in period 1 then 3 mg single dose glucagon nasal powder was administered in period 2.",
      "type" : "person",
      "membership" : "enumerated",
      "characteristic" : [
        {
          "code" : {
            "text" : "Research Study from which this is a flow group"
          },
          "valueReference" : {
            "display" : "NCT03421379"
          },
          "exclude" : false
        }
      ]
    },
    {
      "resourceType" : "Evidence",
      "id" : "NCT03421379-flow-milestone-0-Period-1-group-FG000",
      "meta" : {
        "profile" : [
          🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"
        ]
      },
      "identifier" : [
        {
          "type" : {
            "text" : "FEvIR Linking Identifier"
          },
          "system" : "https://fevir.net/FLI",
          "value" : "NCT03421379-flow-milestone-0-Period-1-group-FG000",
          "assigner" : {
            "display" : "Computable Publishing LLC"
          }
        }
      ],
      "title" : "ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - STARTED at Period 1",
      "status" : "active",
      "author" : [
        {
          "name" : "Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter"
        }
      ],
      "useContext" : [
        {
          "code" : {
            "system" : "https://fevir.net/resources/CodeSystem/179423",
            "code" : "evidence-communication",
            "display" : "Evidence Communication"
          },
          "valueCodeableConcept" : {
            "coding" : [
              {
                "system" : "https://fevir.net/resources/CodeSystem/179423",
                "code" : "ParticipantFlowEvidence",
                "display" : "ParticipantFlowEvidence"
              }
            ]
          }
        }
      ],
      "variableDefinition" : [
        {
          "variableRole" : "population",
          "observed" : {
            "reference" : "#FG000",
            "type" : "Group",
            "display" : "Glucagon Nasal Powder/Glucagon Hydrochloride"
          }
        },
        {
          "variableRole" : "outcome",
          "observed" : {
            "display" : "STARTED at Period 1"
          }
        }
      ],
      "statistic" : [
        {
          "statisticType" : {
            "coding" : [
              {
                "system" : "https://fevir.net/sevco",
                "code" : "STATO:0000047",
                "display" : "Count"
              }
            ]
          },
          "quantity" : {
            "value" : 34
          }
        }
      ]
    },
    {
      "resourceType" : "Evidence",
      "id" : "NCT03421379-flow-milestone-0-Period-1-group-FG001",
      "meta" : {
        "profile" : [
          🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"
        ]
      },
      "identifier" : [
        {
          "type" : {
            "text" : "FEvIR Linking Identifier"
          },
          "system" : "https://fevir.net/FLI",
          "value" : "NCT03421379-flow-milestone-0-Period-1-group-FG001",
          "assigner" : {
            "display" : "Computable Publishing LLC"
          }
        }
      ],
      "title" : "ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - STARTED at Period 1",
      "status" : "active",
      "author" : [
        {
          "name" : "Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter"
        }
      ],
      "useContext" : [
        {
          "code" : {
            "system" : "https://fevir.net/resources/CodeSystem/179423",
            "code" : "evidence-communication",
            "display" : "Evidence Communication"
          },
          "valueCodeableConcept" : {
            "coding" : [
              {
                "system" : "https://fevir.net/resources/CodeSystem/179423",
                "code" : "ParticipantFlowEvidence",
                "display" : "ParticipantFlowEvidence"
              }
            ]
          }
        }
      ],
      "variableDefinition" : [
        {
          "variableRole" : "population",
          "observed" : {
            "reference" : "#FG001",
            "type" : "Group",
            "display" : "Glucagon Hydrochloride Solution/Glucagon Nasal Powder"
          }
        },
        {
          "variableRole" : "outcome",
          "observed" : {
            "display" : "STARTED at Period 1"
          }
        }
      ],
      "statistic" : [
        {
          "statisticType" : {
            "coding" : [
              {
                "system" : "https://fevir.net/sevco",
                "code" : "STATO:0000047",
                "display" : "Count"
              }
            ]
          },
          "quantity" : {
            "value" : 41
          }
        }
      ]
    },
    {
      "resourceType" : "Evidence",
      "id" : "NCT03421379-flow-milestone-1-Period-1-group-FG000",
      "meta" : {
        "profile" : [
          🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"
        ]
      },
      "identifier" : [
        {
          "type" : {
            "text" : "FEvIR Linking Identifier"
          },
          "system" : "https://fevir.net/FLI",
          "value" : "NCT03421379-flow-milestone-1-Period-1-group-FG000",
          "assigner" : {
            "display" : "Computable Publishing LLC"
          }
        }
      ],
      "title" : "ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - Received at Least One Dose of Study Drug at Period 1",
      "status" : "active",
      "author" : [
        {
          "name" : "Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter"
        }
      ],
      "useContext" : [
        {
          "code" : {
            "system" : "https://fevir.net/resources/CodeSystem/179423",
            "code" : "evidence-communication",
            "display" : "Evidence Communication"
          },
          "valueCodeableConcept" : {
            "coding" : [
              {
                "system" : "https://fevir.net/resources/CodeSystem/179423",
                "code" : "ParticipantFlowEvidence",
                "display" : "ParticipantFlowEvidence"
              }
            ]
          }
        }
      ],
      "variableDefinition" : [
        {
          "variableRole" : "population",
          "observed" : {
            "reference" : "#FG000",
            "type" : "Group",
            "display" : "Glucagon Nasal Powder/Glucagon Hydrochloride"
          }
        },
        {
          "variableRole" : "outcome",
          "observed" : {
            "display" : "Received at Least One Dose of Study Drug at Period 1"
          }
        }
      ],
      "statistic" : [
        {
          "statisticType" : {
            "coding" : [
              {
                "system" : "https://fevir.net/sevco",
                "code" : "STATO:0000047",
                "display" : "Count"
              }
            ]
          },
          "quantity" : {
            "value" : 33
          }
        }
      ]
    },
    {
      "resourceType" : "Evidence",
      "id" : "NCT03421379-flow-milestone-1-Period-1-group-FG001",
      "meta" : {
        "profile" : [
          🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"
        ]
      },
      "identifier" : [
        {
          "type" : {
            "text" : "FEvIR Linking Identifier"
          },
          "system" : "https://fevir.net/FLI",
          "value" : "NCT03421379-flow-milestone-1-Period-1-group-FG001",
          "assigner" : {
            "display" : "Computable Publishing LLC"
          }
        }
      ],
      "title" : "ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - Received at Least One Dose of Study Drug at Period 1",
      "status" : "active",
      "author" : [
        {
          "name" : "Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter"
        }
      ],
      "useContext" : [
        {
          "code" : {
            "system" : "https://fevir.net/resources/CodeSystem/179423",
            "code" : "evidence-communication",
            "display" : "Evidence Communication"
          },
          "valueCodeableConcept" : {
            "coding" : [
              {
                "system" : "https://fevir.net/resources/CodeSystem/179423",
                "code" : "ParticipantFlowEvidence",
                "display" : "ParticipantFlowEvidence"
              }
            ]
          }
        }
      ],
      "variableDefinition" : [
        {
          "variableRole" : "population",
          "observed" : {
            "reference" : "#FG001",
            "type" : "Group",
            "display" : "Glucagon Hydrochloride Solution/Glucagon Nasal Powder"
          }
        },
        {
          "variableRole" : "outcome",
          "observed" : {
            "display" : "Received at Least One Dose of Study Drug at Period 1"
          }
        }
      ],
      "statistic" : [
        {
          "statisticType" : {
            "coding" : [
              {
                "system" : "https://fevir.net/sevco",
                "code" : "STATO:0000047",
                "display" : "Count"
              }
            ]
          },
          "quantity" : {
            "value" : 39
          }
        }
      ]
    },
    {
      "resourceType" : "Evidence",
      "id" : "NCT03421379-flow-milestone-2-Period-1-group-FG000",
      "meta" : {
        "profile" : [
          🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"
        ]
      },
      "identifier" : [
        {
          "type" : {
            "text" : "FEvIR Linking Identifier"
          },
          "system" : "https://fevir.net/FLI",
          "value" : "NCT03421379-flow-milestone-2-Period-1-group-FG000",
          "assigner" : {
            "display" : "Computable Publishing LLC"
          }
        }
      ],
      "title" : "ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - COMPLETED at Period 1",
      "status" : "active",
      "author" : [
        {
          "name" : "Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter"
        }
      ],
      "useContext" : [
        {
          "code" : {
            "system" : "https://fevir.net/resources/CodeSystem/179423",
            "code" : "evidence-communication",
            "display" : "Evidence Communication"
          },
          "valueCodeableConcept" : {
            "coding" : [
              {
                "system" : "https://fevir.net/resources/CodeSystem/179423",
                "code" : "ParticipantFlowEvidence",
                "display" : "ParticipantFlowEvidence"
              }
            ]
          }
        }
      ],
      "variableDefinition" : [
        {
          "variableRole" : "population",
          "observed" : {
            "reference" : "#FG000",
            "type" : "Group",
            "display" : "Glucagon Nasal Powder/Glucagon Hydrochloride"
          }
        },
        {
          "variableRole" : "outcome",
          "observed" : {
            "display" : "COMPLETED at Period 1"
          }
        }
      ],
      "statistic" : [
        {
          "statisticType" : {
            "coding" : [
              {
                "system" : "https://fevir.net/sevco",
                "code" : "STATO:0000047",
                "display" : "Count"
              }
            ]
          },
          "quantity" : {
            "value" : 32
          }
        }
      ]
    },
    {
      "resourceType" : "Evidence",
      "id" : "NCT03421379-flow-milestone-2-Period-1-group-FG001",
      "meta" : {
        "profile" : [
          🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"
        ]
      },
      "identifier" : [
        {
          "type" : {
            "text" : "FEvIR Linking Identifier"
          },
          "system" : "https://fevir.net/FLI",
          "value" : "NCT03421379-flow-milestone-2-Period-1-group-FG001",
          "assigner" : {
            "display" : "Computable Publishing LLC"
          }
        }
      ],
      "title" : "ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - COMPLETED at Period 1",
      "status" : "active",
      "author" : [
        {
          "name" : "Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter"
        }
      ],
      "useContext" : [
        {
          "code" : {
            "system" : "https://fevir.net/resources/CodeSystem/179423",
            "code" : "evidence-communication",
            "display" : "Evidence Communication"
          },
          "valueCodeableConcept" : {
            "coding" : [
              {
                "system" : "https://fevir.net/resources/CodeSystem/179423",
                "code" : "ParticipantFlowEvidence",
                "display" : "ParticipantFlowEvidence"
              }
            ]
          }
        }
      ],
      "variableDefinition" : [
        {
          "variableRole" : "population",
          "observed" : {
            "reference" : "#FG001",
            "type" : "Group",
            "display" : "Glucagon Hydrochloride Solution/Glucagon Nasal Powder"
          }
        },
        {
          "variableRole" : "outcome",
          "observed" : {
            "display" : "COMPLETED at Period 1"
          }
        }
      ],
      "statistic" : [
        {
          "statisticType" : {
            "coding" : [
              {
                "system" : "https://fevir.net/sevco",
                "code" : "STATO:0000047",
                "display" : "Count"
              }
            ]
          },
          "quantity" : {
            "value" : 37
          }
        }
      ]
    },
    {
      "resourceType" : "Evidence",
      "id" : "NCT03421379-flow-milestone-3-Period-1-group-FG000",
      "meta" : {
        "profile" : [
          🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"
        ]
      },
      "identifier" : [
        {
          "type" : {
            "text" : "FEvIR Linking Identifier"
          },
          "system" : "https://fevir.net/FLI",
          "value" : "NCT03421379-flow-milestone-3-Period-1-group-FG000",
          "assigner" : {
            "display" : "Computable Publishing LLC"
          }
        }
      ],
      "title" : "ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - NOT COMPLETED at Period 1",
      "status" : "active",
      "author" : [
        {
          "name" : "Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter"
        }
      ],
      "useContext" : [
        {
          "code" : {
            "system" : "https://fevir.net/resources/CodeSystem/179423",
            "code" : "evidence-communication",
            "display" : "Evidence Communication"
          },
          "valueCodeableConcept" : {
            "coding" : [
              {
                "system" : "https://fevir.net/resources/CodeSystem/179423",
                "code" : "ParticipantFlowEvidence",
                "display" : "ParticipantFlowEvidence"
              }
            ]
          }
        }
      ],
      "variableDefinition" : [
        {
          "variableRole" : "population",
          "observed" : {
            "reference" : "#FG000",
            "type" : "Group",
            "display" : "Glucagon Nasal Powder/Glucagon Hydrochloride"
          }
        },
        {
          "variableRole" : "outcome",
          "observed" : {
            "display" : "NOT COMPLETED at Period 1"
          }
        }
      ],
      "statistic" : [
        {
          "statisticType" : {
            "coding" : [
              {
                "system" : "https://fevir.net/sevco",
                "code" : "STATO:0000047",
                "display" : "Count"
              }
            ]
          },
          "quantity" : {
            "value" : 2
          }
        }
      ]
    },
    {
      "resourceType" : "Evidence",
      "id" : "NCT03421379-flow-milestone-3-Period-1-group-FG001",
      "meta" : {
        "profile" : [
          🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"
        ]
      },
      "identifier" : [
        {
          "type" : {
            "text" : "FEvIR Linking Identifier"
          },
          "system" : "https://fevir.net/FLI",
          "value" : "NCT03421379-flow-milestone-3-Period-1-group-FG001",
          "assigner" : {
            "display" : "Computable Publishing LLC"
          }
        }
      ],
      "title" : "ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - NOT COMPLETED at Period 1",
      "status" : "active",
      "author" : [
        {
          "name" : "Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter"
        }
      ],
      "useContext" : [
        {
          "code" : {
            "system" : "https://fevir.net/resources/CodeSystem/179423",
            "code" : "evidence-communication",
            "display" : "Evidence Communication"
          },
          "valueCodeableConcept" : {
            "coding" : [
              {
                "system" : "https://fevir.net/resources/CodeSystem/179423",
                "code" : "ParticipantFlowEvidence",
                "display" : "ParticipantFlowEvidence"
              }
            ]
          }
        }
      ],
      "variableDefinition" : [
        {
          "variableRole" : "population",
          "observed" : {
            "reference" : "#FG001",
            "type" : "Group",
            "display" : "Glucagon Hydrochloride Solution/Glucagon Nasal Powder"
          }
        },
        {
          "variableRole" : "outcome",
          "observed" : {
            "display" : "NOT COMPLETED at Period 1"
          }
        }
      ],
      "statistic" : [
        {
          "statisticType" : {
            "coding" : [
              {
                "system" : "https://fevir.net/sevco",
                "code" : "STATO:0000047",
                "display" : "Count"
              }
            ]
          },
          "quantity" : {
            "value" : 4
          }
        }
      ]
    },
    {
      "resourceType" : "Evidence",
      "id" : "NCT03421379-flow-reason-Period-1-group-FG000",
      "meta" : {
        "profile" : [
          🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"
        ]
      },
      "identifier" : [
        {
          "type" : {
            "text" : "FEvIR Linking Identifier"
          },
          "system" : "https://fevir.net/FLI",
          "value" : "NCT03421379-flow-reason-Period-1-group-FG000",
          "assigner" : {
            "display" : "Computable Publishing LLC"
          }
        }
      ],
      "title" : "ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - Reasons for withdraw at Period 1",
      "status" : "active",
      "author" : [
        {
          "name" : "Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter"
        }
      ],
      "useContext" : [
        {
          "code" : {
            "system" : "https://fevir.net/resources/CodeSystem/179423",
            "code" : "evidence-communication",
            "display" : "Evidence Communication"
          },
          "valueCodeableConcept" : {
            "coding" : [
              {
                "system" : "https://fevir.net/resources/CodeSystem/179423",
                "code" : "ParticipantFlowEvidence",
                "display" : "ParticipantFlowEvidence"
              }
            ]
          }
        }
      ],
      "variableDefinition" : [
        {
          "variableRole" : "population",
          "observed" : {
            "reference" : "#FG000",
            "type" : "Group",
            "display" : "Glucagon Nasal Powder/Glucagon Hydrochloride"
          }
        },
        {
          "variableRole" : "outcome",
          "observed" : {
            "display" : "Reasons for withdraw at Period 1"
          }
        }
      ],
      "statistic" : [
        {
          "statisticType" : {
            "coding" : [
              {
                "system" : "https://fevir.net/sevco",
                "code" : "STATO:0000047",
                "display" : "Count"
              }
            ]
          },
          "category" : {
            "text" : "Withdrawal by Subject"
          },
          "quantity" : {
            "value" : 0
          }
        },
        {
          "statisticType" : {
            "coding" : [
              {
                "system" : "https://fevir.net/sevco",
                "code" : "STATO:0000047",
                "display" : "Count"
              }
            ]
          },
          "category" : {
            "text" : "Physician Decision"
          },
          "quantity" : {
            "value" : 1
          }
        },
        {
          "statisticType" : {
            "coding" : [
              {
                "system" : "https://fevir.net/sevco",
                "code" : "STATO:0000047",
                "display" : "Count"
              }
            ]
          },
          "category" : {
            "text" : "Did not receive treatment"
          },
          "quantity" : {
            "value" : 1
          }
        }
      ]
    },
    {
      "resourceType" : "Evidence",
      "id" : "NCT03421379-flow-reason-Period-1-group-FG001",
      "meta" : {
        "profile" : [
          🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"
        ]
      },
      "identifier" : [
        {
          "type" : {
            "text" : "FEvIR Linking Identifier"
          },
          "system" : "https://fevir.net/FLI",
          "value" : "NCT03421379-flow-reason-Period-1-group-FG001",
          "assigner" : {
            "display" : "Computable Publishing LLC"
          }
        }
      ],
      "title" : "ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - Reasons for withdraw at Period 1",
      "status" : "active",
      "author" : [
        {
          "name" : "Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter"
        }
      ],
      "useContext" : [
        {
          "code" : {
            "system" : "https://fevir.net/resources/CodeSystem/179423",
            "code" : "evidence-communication",
            "display" : "Evidence Communication"
          },
          "valueCodeableConcept" : {
            "coding" : [
              {
                "system" : "https://fevir.net/resources/CodeSystem/179423",
                "code" : "ParticipantFlowEvidence",
                "display" : "ParticipantFlowEvidence"
              }
            ]
          }
        }
      ],
      "variableDefinition" : [
        {
          "variableRole" : "population",
          "observed" : {
            "reference" : "#FG001",
            "type" : "Group",
            "display" : "Glucagon Hydrochloride Solution/Glucagon Nasal Powder"
          }
        },
        {
          "variableRole" : "outcome",
          "observed" : {
            "display" : "Reasons for withdraw at Period 1"
          }
        }
      ],
      "statistic" : [
        {
          "statisticType" : {
            "coding" : [
              {
                "system" : "https://fevir.net/sevco",
                "code" : "STATO:0000047",
                "display" : "Count"
              }
            ]
          },
          "category" : {
            "text" : "Withdrawal by Subject"
          },
          "quantity" : {
            "value" : 1
          }
        },
        {
          "statisticType" : {
            "coding" : [
              {
                "system" : "https://fevir.net/sevco",
                "code" : "STATO:0000047",
                "display" : "Count"
              }
            ]
          },
          "category" : {
            "text" : "Physician Decision"
          },
          "quantity" : {
            "value" : 1
          }
        },
        {
          "statisticType" : {
            "coding" : [
              {
                "system" : "https://fevir.net/sevco",
                "code" : "STATO:0000047",
                "display" : "Count"
              }
            ]
          },
          "category" : {
            "text" : "Did not receive treatment"
          },
          "quantity" : {
            "value" : 2
          }
        }
      ]
    },
    {
      "resourceType" : "Evidence",
      "id" : "NCT03421379-flow-milestone-0-Washout-Period--OPEN---3-to-1-FG000",
      "meta" : {
        "profile" : [
          🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"
        ]
      },
      "identifier" : [
        {
          "type" : {
            "text" : "FEvIR Linking Identifier"
          },
          "system" : "https://fevir.net/FLI",
          "value" : "NCT03421379-flow-milestone-0-Washout-Period--OPEN---3-to-1-FG000",
          "assigner" : {
            "display" : "Computable Publishing LLC"
          }
        }
      ],
      "title" : "ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - STARTED at Washout Period (3 to 14 Days)",
      "status" : "active",
      "author" : [
        {
          "name" : "Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter"
        }
      ],
      "useContext" : [
        {
          "code" : {
            "system" : "https://fevir.net/resources/CodeSystem/179423",
            "code" : "evidence-communication",
            "display" : "Evidence Communication"
          },
          "valueCodeableConcept" : {
            "coding" : [
              {
                "system" : "https://fevir.net/resources/CodeSystem/179423",
                "code" : "ParticipantFlowEvidence",
                "display" : "ParticipantFlowEvidence"
              }
            ]
          }
        }
      ],
      "variableDefinition" : [
        {
          "variableRole" : "population",
          "observed" : {
            "reference" : "#FG000",
            "type" : "Group",
            "display" : "Glucagon Nasal Powder/Glucagon Hydrochloride"
          }
        },
        {
          "variableRole" : "outcome",
          "observed" : {
            "display" : "STARTED at Washout Period (3 to 14 Days)"
          }
        }
      ],
      "statistic" : [
        {
          "statisticType" : {
            "coding" : [
              {
                "system" : "https://fevir.net/sevco",
                "code" : "STATO:0000047",
                "display" : "Count"
              }
            ]
          },
          "quantity" : {
            "value" : 32
          }
        }
      ]
    },
    {
      "resourceType" : "Evidence",
      "id" : "NCT03421379-flow-milestone-0-Washout-Period--OPEN---3-to-1-FG001",
      "meta" : {
        "profile" : [
          🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"
        ]
      },
      "identifier" : [
        {
          "type" : {
            "text" : "FEvIR Linking Identifier"
          },
          "system" : "https://fevir.net/FLI",
          "value" : "NCT03421379-flow-milestone-0-Washout-Period--OPEN---3-to-1-FG001",
          "assigner" : {
            "display" : "Computable Publishing LLC"
          }
        }
      ],
      "title" : "ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - STARTED at Washout Period (3 to 14 Days)",
      "status" : "active",
      "author" : [
        {
          "name" : "Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter"
        }
      ],
      "useContext" : [
        {
          "code" : {
            "system" : "https://fevir.net/resources/CodeSystem/179423",
            "code" : "evidence-communication",
            "display" : "Evidence Communication"
          },
          "valueCodeableConcept" : {
            "coding" : [
              {
                "system" : "https://fevir.net/resources/CodeSystem/179423",
                "code" : "ParticipantFlowEvidence",
                "display" : "ParticipantFlowEvidence"
              }
            ]
          }
        }
      ],
      "variableDefinition" : [
        {
          "variableRole" : "population",
          "observed" : {
            "reference" : "#FG001",
            "type" : "Group",
            "display" : "Glucagon Hydrochloride Solution/Glucagon Nasal Powder"
          }
        },
        {
          "variableRole" : "outcome",
          "observed" : {
            "display" : "STARTED at Washout Period (3 to 14 Days)"
          }
        }
      ],
      "statistic" : [
        {
          "statisticType" : {
            "coding" : [
              {
                "system" : "https://fevir.net/sevco",
                "code" : "STATO:0000047",
                "display" : "Count"
              }
            ]
          },
          "quantity" : {
            "value" : 37
          }
        }
      ]
    },
    {
      "resourceType" : "Evidence",
      "id" : "NCT03421379-flow-milestone-1-Washout-Period--OPEN---3-to-1-FG000",
      "meta" : {
        "profile" : [
          🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"
        ]
      },
      "identifier" : [
        {
          "type" : {
            "text" : "FEvIR Linking Identifier"
          },
          "system" : "https://fevir.net/FLI",
          "value" : "NCT03421379-flow-milestone-1-Washout-Period--OPEN---3-to-1-FG000",
          "assigner" : {
            "display" : "Computable Publishing LLC"
          }
        }
      ],
      "title" : "ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - COMPLETED at Washout Period (3 to 14 Days)",
      "status" : "active",
      "author" : [
        {
          "name" : "Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter"
        }
      ],
      "useContext" : [
        {
          "code" : {
            "system" : "https://fevir.net/resources/CodeSystem/179423",
            "code" : "evidence-communication",
            "display" : "Evidence Communication"
          },
          "valueCodeableConcept" : {
            "coding" : [
              {
                "system" : "https://fevir.net/resources/CodeSystem/179423",
                "code" : "ParticipantFlowEvidence",
                "display" : "ParticipantFlowEvidence"
              }
            ]
          }
        }
      ],
      "variableDefinition" : [
        {
          "variableRole" : "population",
          "observed" : {
            "reference" : "#FG000",
            "type" : "Group",
            "display" : "Glucagon Nasal Powder/Glucagon Hydrochloride"
          }
        },
        {
          "variableRole" : "outcome",
          "observed" : {
            "display" : "COMPLETED at Washout Period (3 to 14 Days)"
          }
        }
      ],
      "statistic" : [
        {
          "statisticType" : {
            "coding" : [
              {
                "system" : "https://fevir.net/sevco",
                "code" : "STATO:0000047",
                "display" : "Count"
              }
            ]
          },
          "quantity" : {
            "value" : 32
          }
        }
      ]
    },
    {
      "resourceType" : "Evidence",
      "id" : "NCT03421379-flow-milestone-1-Washout-Period--OPEN---3-to-1-FG001",
      "meta" : {
        "profile" : [
          🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"
        ]
      },
      "identifier" : [
        {
          "type" : {
            "text" : "FEvIR Linking Identifier"
          },
          "system" : "https://fevir.net/FLI",
          "value" : "NCT03421379-flow-milestone-1-Washout-Period--OPEN---3-to-1-FG001",
          "assigner" : {
            "display" : "Computable Publishing LLC"
          }
        }
      ],
      "title" : "ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - COMPLETED at Washout Period (3 to 14 Days)",
      "status" : "active",
      "author" : [
        {
          "name" : "Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter"
        }
      ],
      "useContext" : [
        {
          "code" : {
            "system" : "https://fevir.net/resources/CodeSystem/179423",
            "code" : "evidence-communication",
            "display" : "Evidence Communication"
          },
          "valueCodeableConcept" : {
            "coding" : [
              {
                "system" : "https://fevir.net/resources/CodeSystem/179423",
                "code" : "ParticipantFlowEvidence",
                "display" : "ParticipantFlowEvidence"
              }
            ]
          }
        }
      ],
      "variableDefinition" : [
        {
          "variableRole" : "population",
          "observed" : {
            "reference" : "#FG001",
            "type" : "Group",
            "display" : "Glucagon Hydrochloride Solution/Glucagon Nasal Powder"
          }
        },
        {
          "variableRole" : "outcome",
          "observed" : {
            "display" : "COMPLETED at Washout Period (3 to 14 Days)"
          }
        }
      ],
      "statistic" : [
        {
          "statisticType" : {
            "coding" : [
              {
                "system" : "https://fevir.net/sevco",
                "code" : "STATO:0000047",
                "display" : "Count"
              }
            ]
          },
          "quantity" : {
            "value" : 37
          }
        }
      ]
    },
    {
      "resourceType" : "Evidence",
      "id" : "NCT03421379-flow-milestone-2-Washout-Period--OPEN---3-to-1-FG000",
      "meta" : {
        "profile" : [
          🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"
        ]
      },
      "identifier" : [
        {
          "type" : {
            "text" : "FEvIR Linking Identifier"
          },
          "system" : "https://fevir.net/FLI",
          "value" : "NCT03421379-flow-milestone-2-Washout-Period--OPEN---3-to-1-FG000",
          "assigner" : {
            "display" : "Computable Publishing LLC"
          }
        }
      ],
      "title" : "ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - NOT COMPLETED at Washout Period (3 to 14 Days)",
      "status" : "active",
      "author" : [
        {
          "name" : "Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter"
        }
      ],
      "useContext" : [
        {
          "code" : {
            "system" : "https://fevir.net/resources/CodeSystem/179423",
            "code" : "evidence-communication",
            "display" : "Evidence Communication"
          },
          "valueCodeableConcept" : {
            "coding" : [
              {
                "system" : "https://fevir.net/resources/CodeSystem/179423",
                "code" : "ParticipantFlowEvidence",
                "display" : "ParticipantFlowEvidence"
              }
            ]
          }
        }
      ],
      "variableDefinition" : [
        {
          "variableRole" : "population",
          "observed" : {
            "reference" : "#FG000",
            "type" : "Group",
            "display" : "Glucagon Nasal Powder/Glucagon Hydrochloride"
          }
        },
        {
          "variableRole" : "outcome",
          "observed" : {
            "display" : "NOT COMPLETED at Washout Period (3 to 14 Days)"
          }
        }
      ],
      "statistic" : [
        {
          "statisticType" : {
            "coding" : [
              {
                "system" : "https://fevir.net/sevco",
                "code" : "STATO:0000047",
                "display" : "Count"
              }
            ]
          },
          "quantity" : {
            "value" : 0
          }
        }
      ]
    },
    {
      "resourceType" : "Evidence",
      "id" : "NCT03421379-flow-milestone-2-Washout-Period--OPEN---3-to-1-FG001",
      "meta" : {
        "profile" : [
          🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"
        ]
      },
      "identifier" : [
        {
          "type" : {
            "text" : "FEvIR Linking Identifier"
          },
          "system" : "https://fevir.net/FLI",
          "value" : "NCT03421379-flow-milestone-2-Washout-Period--OPEN---3-to-1-FG001",
          "assigner" : {
            "display" : "Computable Publishing LLC"
          }
        }
      ],
      "title" : "ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - NOT COMPLETED at Washout Period (3 to 14 Days)",
      "status" : "active",
      "author" : [
        {
          "name" : "Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter"
        }
      ],
      "useContext" : [
        {
          "code" : {
            "system" : "https://fevir.net/resources/CodeSystem/179423",
            "code" : "evidence-communication",
            "display" : "Evidence Communication"
          },
          "valueCodeableConcept" : {
            "coding" : [
              {
                "system" : "https://fevir.net/resources/CodeSystem/179423",
                "code" : "ParticipantFlowEvidence",
                "display" : "ParticipantFlowEvidence"
              }
            ]
          }
        }
      ],
      "variableDefinition" : [
        {
          "variableRole" : "population",
          "observed" : {
            "reference" : "#FG001",
            "type" : "Group",
            "display" : "Glucagon Hydrochloride Solution/Glucagon Nasal Powder"
          }
        },
        {
          "variableRole" : "outcome",
          "observed" : {
            "display" : "NOT COMPLETED at Washout Period (3 to 14 Days)"
          }
        }
      ],
      "statistic" : [
        {
          "statisticType" : {
            "coding" : [
              {
                "system" : "https://fevir.net/sevco",
                "code" : "STATO:0000047",
                "display" : "Count"
              }
            ]
          },
          "quantity" : {
            "value" : 0
          }
        }
      ]
    },
    {
      "resourceType" : "Evidence",
      "id" : "NCT03421379-flow-milestone-0-Period-2-group-FG000",
      "meta" : {
        "profile" : [
          🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"
        ]
      },
      "identifier" : [
        {
          "type" : {
            "text" : "FEvIR Linking Identifier"
          },
          "system" : "https://fevir.net/FLI",
          "value" : "NCT03421379-flow-milestone-0-Period-2-group-FG000",
          "assigner" : {
            "display" : "Computable Publishing LLC"
          }
        }
      ],
      "title" : "ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - STARTED at Period 2",
      "status" : "active",
      "author" : [
        {
          "name" : "Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter"
        }
      ],
      "useContext" : [
        {
          "code" : {
            "system" : "https://fevir.net/resources/CodeSystem/179423",
            "code" : "evidence-communication",
            "display" : "Evidence Communication"
          },
          "valueCodeableConcept" : {
            "coding" : [
              {
                "system" : "https://fevir.net/resources/CodeSystem/179423",
                "code" : "ParticipantFlowEvidence",
                "display" : "ParticipantFlowEvidence"
              }
            ]
          }
        }
      ],
      "variableDefinition" : [
        {
          "variableRole" : "population",
          "observed" : {
            "reference" : "#FG000",
            "type" : "Group",
            "display" : "Glucagon Nasal Powder/Glucagon Hydrochloride"
          }
        },
        {
          "variableRole" : "outcome",
          "observed" : {
            "display" : "STARTED at Period 2"
          }
        }
      ],
      "statistic" : [
        {
          "statisticType" : {
            "coding" : [
              {
                "system" : "https://fevir.net/sevco",
                "code" : "STATO:0000047",
                "display" : "Count"
              }
            ]
          },
          "quantity" : {
            "value" : 32
          }
        }
      ]
    },
    {
      "resourceType" : "Evidence",
      "id" : "NCT03421379-flow-milestone-0-Period-2-group-FG001",
      "meta" : {
        "profile" : [
          🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"
        ]
      },
      "identifier" : [
        {
          "type" : {
            "text" : "FEvIR Linking Identifier"
          },
          "system" : "https://fevir.net/FLI",
          "value" : "NCT03421379-flow-milestone-0-Period-2-group-FG001",
          "assigner" : {
            "display" : "Computable Publishing LLC"
          }
        }
      ],
      "title" : "ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - STARTED at Period 2",
      "status" : "active",
      "author" : [
        {
          "name" : "Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter"
        }
      ],
      "useContext" : [
        {
          "code" : {
            "system" : "https://fevir.net/resources/CodeSystem/179423",
            "code" : "evidence-communication",
            "display" : "Evidence Communication"
          },
          "valueCodeableConcept" : {
            "coding" : [
              {
                "system" : "https://fevir.net/resources/CodeSystem/179423",
                "code" : "ParticipantFlowEvidence",
                "display" : "ParticipantFlowEvidence"
              }
            ]
          }
        }
      ],
      "variableDefinition" : [
        {
          "variableRole" : "population",
          "observed" : {
            "reference" : "#FG001",
            "type" : "Group",
            "display" : "Glucagon Hydrochloride Solution/Glucagon Nasal Powder"
          }
        },
        {
          "variableRole" : "outcome",
          "observed" : {
            "display" : "STARTED at Period 2"
          }
        }
      ],
      "statistic" : [
        {
          "statisticType" : {
            "coding" : [
              {
                "system" : "https://fevir.net/sevco",
                "code" : "STATO:0000047",
                "display" : "Count"
              }
            ]
          },
          "quantity" : {
            "value" : 37
          }
        }
      ]
    },
    {
      "resourceType" : "Evidence",
      "id" : "NCT03421379-flow-milestone-1-Period-2-group-FG000",
      "meta" : {
        "profile" : [
          🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"
        ]
      },
      "identifier" : [
        {
          "type" : {
            "text" : "FEvIR Linking Identifier"
          },
          "system" : "https://fevir.net/FLI",
          "value" : "NCT03421379-flow-milestone-1-Period-2-group-FG000",
          "assigner" : {
            "display" : "Computable Publishing LLC"
          }
        }
      ],
      "title" : "ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - COMPLETED at Period 2",
      "status" : "active",
      "author" : [
        {
          "name" : "Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter"
        }
      ],
      "useContext" : [
        {
          "code" : {
            "system" : "https://fevir.net/resources/CodeSystem/179423",
            "code" : "evidence-communication",
            "display" : "Evidence Communication"
          },
          "valueCodeableConcept" : {
            "coding" : [
              {
                "system" : "https://fevir.net/resources/CodeSystem/179423",
                "code" : "ParticipantFlowEvidence",
                "display" : "ParticipantFlowEvidence"
              }
            ]
          }
        }
      ],
      "variableDefinition" : [
        {
          "variableRole" : "population",
          "observed" : {
            "reference" : "#FG000",
            "type" : "Group",
            "display" : "Glucagon Nasal Powder/Glucagon Hydrochloride"
          }
        },
        {
          "variableRole" : "outcome",
          "observed" : {
            "display" : "COMPLETED at Period 2"
          }
        }
      ],
      "statistic" : [
        {
          "statisticType" : {
            "coding" : [
              {
                "system" : "https://fevir.net/sevco",
                "code" : "STATO:0000047",
                "display" : "Count"
              }
            ]
          },
          "quantity" : {
            "value" : 32
          }
        }
      ]
    },
    {
      "resourceType" : "Evidence",
      "id" : "NCT03421379-flow-milestone-1-Period-2-group-FG001",
      "meta" : {
        "profile" : [
          🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"
        ]
      },
      "identifier" : [
        {
          "type" : {
            "text" : "FEvIR Linking Identifier"
          },
          "system" : "https://fevir.net/FLI",
          "value" : "NCT03421379-flow-milestone-1-Period-2-group-FG001",
          "assigner" : {
            "display" : "Computable Publishing LLC"
          }
        }
      ],
      "title" : "ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - COMPLETED at Period 2",
      "status" : "active",
      "author" : [
        {
          "name" : "Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter"
        }
      ],
      "useContext" : [
        {
          "code" : {
            "system" : "https://fevir.net/resources/CodeSystem/179423",
            "code" : "evidence-communication",
            "display" : "Evidence Communication"
          },
          "valueCodeableConcept" : {
            "coding" : [
              {
                "system" : "https://fevir.net/resources/CodeSystem/179423",
                "code" : "ParticipantFlowEvidence",
                "display" : "ParticipantFlowEvidence"
              }
            ]
          }
        }
      ],
      "variableDefinition" : [
        {
          "variableRole" : "population",
          "observed" : {
            "reference" : "#FG001",
            "type" : "Group",
            "display" : "Glucagon Hydrochloride Solution/Glucagon Nasal Powder"
          }
        },
        {
          "variableRole" : "outcome",
          "observed" : {
            "display" : "COMPLETED at Period 2"
          }
        }
      ],
      "statistic" : [
        {
          "statisticType" : {
            "coding" : [
              {
                "system" : "https://fevir.net/sevco",
                "code" : "STATO:0000047",
                "display" : "Count"
              }
            ]
          },
          "quantity" : {
            "value" : 37
          }
        }
      ]
    },
    {
      "resourceType" : "Evidence",
      "id" : "NCT03421379-flow-milestone-2-Period-2-group-FG000",
      "meta" : {
        "profile" : [
          🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"
        ]
      },
      "identifier" : [
        {
          "type" : {
            "text" : "FEvIR Linking Identifier"
          },
          "system" : "https://fevir.net/FLI",
          "value" : "NCT03421379-flow-milestone-2-Period-2-group-FG000",
          "assigner" : {
            "display" : "Computable Publishing LLC"
          }
        }
      ],
      "title" : "ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - NOT COMPLETED at Period 2",
      "status" : "active",
      "author" : [
        {
          "name" : "Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter"
        }
      ],
      "useContext" : [
        {
          "code" : {
            "system" : "https://fevir.net/resources/CodeSystem/179423",
            "code" : "evidence-communication",
            "display" : "Evidence Communication"
          },
          "valueCodeableConcept" : {
            "coding" : [
              {
                "system" : "https://fevir.net/resources/CodeSystem/179423",
                "code" : "ParticipantFlowEvidence",
                "display" : "ParticipantFlowEvidence"
              }
            ]
          }
        }
      ],
      "variableDefinition" : [
        {
          "variableRole" : "population",
          "observed" : {
            "reference" : "#FG000",
            "type" : "Group",
            "display" : "Glucagon Nasal Powder/Glucagon Hydrochloride"
          }
        },
        {
          "variableRole" : "outcome",
          "observed" : {
            "display" : "NOT COMPLETED at Period 2"
          }
        }
      ],
      "statistic" : [
        {
          "statisticType" : {
            "coding" : [
              {
                "system" : "https://fevir.net/sevco",
                "code" : "STATO:0000047",
                "display" : "Count"
              }
            ]
          },
          "quantity" : {
            "value" : 0
          }
        }
      ]
    },
    {
      "resourceType" : "Evidence",
      "id" : "NCT03421379-flow-milestone-2-Period-2-group-FG001",
      "meta" : {
        "profile" : [
          🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"
        ]
      },
      "identifier" : [
        {
          "type" : {
            "text" : "FEvIR Linking Identifier"
          },
          "system" : "https://fevir.net/FLI",
          "value" : "NCT03421379-flow-milestone-2-Period-2-group-FG001",
          "assigner" : {
            "display" : "Computable Publishing LLC"
          }
        }
      ],
      "title" : "ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - NOT COMPLETED at Period 2",
      "status" : "active",
      "author" : [
        {
          "name" : "Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter"
        }
      ],
      "useContext" : [
        {
          "code" : {
            "system" : "https://fevir.net/resources/CodeSystem/179423",
            "code" : "evidence-communication",
            "display" : "Evidence Communication"
          },
          "valueCodeableConcept" : {
            "coding" : [
              {
                "system" : "https://fevir.net/resources/CodeSystem/179423",
                "code" : "ParticipantFlowEvidence",
                "display" : "ParticipantFlowEvidence"
              }
            ]
          }
        }
      ],
      "variableDefinition" : [
        {
          "variableRole" : "population",
          "observed" : {
            "reference" : "#FG001",
            "type" : "Group",
            "display" : "Glucagon Hydrochloride Solution/Glucagon Nasal Powder"
          }
        },
        {
          "variableRole" : "outcome",
          "observed" : {
            "display" : "NOT COMPLETED at Period 2"
          }
        }
      ],
      "statistic" : [
        {
          "statisticType" : {
            "coding" : [
              {
                "system" : "https://fevir.net/sevco",
                "code" : "STATO:0000047",
                "display" : "Count"
              }
            ]
          },
          "quantity" : {
            "value" : 0
          }
        }
      ]
    }
  ],
  "url" : "https://fevir.net/resources/Composition/399871",
  "identifier" : [
    {
      "type" : {
        "coding" : [
          {
            "system" : "http://terminology.hl7.org/CodeSystem/v2-0203",
            "code" : "ACSN",
            "display" : "Accession ID"
          }
        ],
        "text" : "FEvIR Object Identifier"
      },
      "system" : "https://fevir.net/FOI",
      "value" : "399871",
      "assigner" : {
        "display" : "Computable Publishing LLC"
      }
    },
    {
      "type" : {
        "text" : "FEvIR Linking Identifier"
      },
      "system" : "https://fevir.net/FLI",
      "value" : "NCT03421379-participant-flow-report",
      "assigner" : {
        "display" : "Computable Publishing LLC"
      }
    }
  ],
  "status" : "final",
  "type" : {
    "coding" : [
      {
        "system" : "https://fevir.net/resources/CodeSystem/179423",
        "code" : "ParticipantFlowReport",
        "display" : "ParticipantFlowReport"
      }
    ],
    "text" : "Participant Flow Report"
  },
  "date" : "2025-12-11T20:35:21.032Z",
  "author" : [
    {
      "display" : "[No author listed.]"
    }
  ],
  "title" : "Participant Flow Report for NCT03421379",
  "custodian" : {
    🔗 "reference" : "Organization/118079",
    "type" : "Organization",
    "display" : "Computable Publishing LLC"
  },
  "relatesTo" : [
    {
      "type" : "cite-as",
      "targetMarkdown" : "Participant Flow Report for NCT03421379 [Database Entry: FHIR Composition Resource]. Contributors: [No author listed.] [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 399871. Revised 2025-12-11. Available at: https://fevir.net/resources/Composition/399871. Computable resource at: https://fevir.net/resources/Composition/399871#json."
    }
  ],
  "section" : [
    {
      "title" : "Flow PreAssignment Details",
      "code" : {
        "coding" : [
          {
            "system" : "https://fevir.net/resources/CodeSystem/179423",
            "code" : "participant-flow-details",
            "display" : "Participant Flow Details"
          }
        ],
        "text" : "FlowPreAssignmentDetails"
      },
      "text" : {
        "status" : "generated",
        "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Participants were randomized to receive either nasal glucagon or intramuscular (IM) glucagon in the first period, followed by the alternate treatment in the second period.</div>"
      }
    },
    {
      "title" : "Flow Group List",
      "code" : {
        "text" : "FlowGroupList"
      },
      "text" : {
        "status" : "generated",
        "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Glucagon Nasal Powder/Glucagon Hydrochloride, Glucagon Hydrochloride Solution/Glucagon Nasal Powder</div>"
      },
      "entry" : [
        {
          "reference" : "#FG000",
          "type" : "Group",
          "display" : "Glucagon Nasal Powder/Glucagon Hydrochloride"
        },
        {
          "reference" : "#FG001",
          "type" : "Group",
          "display" : "Glucagon Hydrochloride Solution/Glucagon Nasal Powder"
        }
      ]
    },
    {
      "title" : "STARTED at Period 1",
      "code" : {
        "coding" : [
          {
            "system" : "https://fevir.net/resources/CodeSystem/179423",
            "code" : "results",
            "display" : "Results"
          }
        ],
        "text" : "Participant Flow Results"
      },
      "focus" : {
        "display" : "STARTED at Period 1"
      },
      "text" : {
        "status" : "empty",
        "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>"
      },
      "entry" : [
        {
          "reference" : "#NCT03421379-flow-milestone-0-Period-1-group-FG000",
          "type" : "Evidence",
          "display" : "ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - STARTED at Period 1"
        },
        {
          "reference" : "#NCT03421379-flow-milestone-0-Period-1-group-FG001",
          "type" : "Evidence",
          "display" : "ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - STARTED at Period 1"
        }
      ]
    },
    {
      "title" : "Received at Least One Dose of Study Drug at Period 1",
      "code" : {
        "coding" : [
          {
            "system" : "https://fevir.net/resources/CodeSystem/179423",
            "code" : "results",
            "display" : "Results"
          }
        ],
        "text" : "Participant Flow Results"
      },
      "focus" : {
        "display" : "Received at Least One Dose of Study Drug at Period 1"
      },
      "text" : {
        "status" : "empty",
        "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>"
      },
      "entry" : [
        {
          "reference" : "#NCT03421379-flow-milestone-1-Period-1-group-FG000",
          "type" : "Evidence",
          "display" : "ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - Received at Least One Dose of Study Drug at Period 1"
        },
        {
          "reference" : "#NCT03421379-flow-milestone-1-Period-1-group-FG001",
          "type" : "Evidence",
          "display" : "ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - Received at Least One Dose of Study Drug at Period 1"
        }
      ]
    },
    {
      "title" : "COMPLETED at Period 1",
      "code" : {
        "coding" : [
          {
            "system" : "https://fevir.net/resources/CodeSystem/179423",
            "code" : "results",
            "display" : "Results"
          }
        ],
        "text" : "Participant Flow Results"
      },
      "focus" : {
        "display" : "COMPLETED at Period 1"
      },
      "text" : {
        "status" : "empty",
        "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>"
      },
      "entry" : [
        {
          "reference" : "#NCT03421379-flow-milestone-2-Period-1-group-FG000",
          "type" : "Evidence",
          "display" : "ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - COMPLETED at Period 1"
        },
        {
          "reference" : "#NCT03421379-flow-milestone-2-Period-1-group-FG001",
          "type" : "Evidence",
          "display" : "ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - COMPLETED at Period 1"
        }
      ]
    },
    {
      "title" : "NOT COMPLETED at Period 1",
      "code" : {
        "coding" : [
          {
            "system" : "https://fevir.net/resources/CodeSystem/179423",
            "code" : "results",
            "display" : "Results"
          }
        ],
        "text" : "Participant Flow Results"
      },
      "focus" : {
        "display" : "NOT COMPLETED at Period 1"
      },
      "text" : {
        "status" : "empty",
        "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>"
      },
      "entry" : [
        {
          "reference" : "#NCT03421379-flow-milestone-3-Period-1-group-FG000",
          "type" : "Evidence",
          "display" : "ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - NOT COMPLETED at Period 1"
        },
        {
          "reference" : "#NCT03421379-flow-milestone-3-Period-1-group-FG001",
          "type" : "Evidence",
          "display" : "ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - NOT COMPLETED at Period 1"
        }
      ]
    },
    {
      "title" : "Reasons for withdraw at Period 1",
      "code" : {
        "coding" : [
          {
            "system" : "https://fevir.net/resources/CodeSystem/179423",
            "code" : "results",
            "display" : "Results"
          }
        ],
        "text" : "Participant Flow Results"
      },
      "focus" : {
        "display" : "Reasons for withdraw at Period 1"
      },
      "text" : {
        "status" : "empty",
        "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>"
      },
      "entry" : [
        {
          "reference" : "#NCT03421379-flow-reason-Period-1-group-FG000",
          "type" : "Evidence",
          "display" : "ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - Reasons for withdraw at Period 1"
        },
        {
          "reference" : "#NCT03421379-flow-reason-Period-1-group-FG001",
          "type" : "Evidence",
          "display" : "ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - Reasons for withdraw at Period 1"
        }
      ]
    },
    {
      "title" : "STARTED at Washout Period (3 to 14 Days)",
      "code" : {
        "coding" : [
          {
            "system" : "https://fevir.net/resources/CodeSystem/179423",
            "code" : "results",
            "display" : "Results"
          }
        ],
        "text" : "Participant Flow Results"
      },
      "focus" : {
        "display" : "STARTED at Washout Period (3 to 14 Days)"
      },
      "text" : {
        "status" : "empty",
        "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>"
      },
      "entry" : [
        {
          "reference" : "#NCT03421379-flow-milestone-0-Washout-Period--OPEN---3-to-1-FG000",
          "type" : "Evidence",
          "display" : "ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - STARTED at Washout Period (3 to 14 Days)"
        },
        {
          "reference" : "#NCT03421379-flow-milestone-0-Washout-Period--OPEN---3-to-1-FG001",
          "type" : "Evidence",
          "display" : "ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - STARTED at Washout Period (3 to 14 Days)"
        }
      ]
    },
    {
      "title" : "COMPLETED at Washout Period (3 to 14 Days)",
      "code" : {
        "coding" : [
          {
            "system" : "https://fevir.net/resources/CodeSystem/179423",
            "code" : "results",
            "display" : "Results"
          }
        ],
        "text" : "Participant Flow Results"
      },
      "focus" : {
        "display" : "COMPLETED at Washout Period (3 to 14 Days)"
      },
      "text" : {
        "status" : "empty",
        "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>"
      },
      "entry" : [
        {
          "reference" : "#NCT03421379-flow-milestone-1-Washout-Period--OPEN---3-to-1-FG000",
          "type" : "Evidence",
          "display" : "ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - COMPLETED at Washout Period (3 to 14 Days)"
        },
        {
          "reference" : "#NCT03421379-flow-milestone-1-Washout-Period--OPEN---3-to-1-FG001",
          "type" : "Evidence",
          "display" : "ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - COMPLETED at Washout Period (3 to 14 Days)"
        }
      ]
    },
    {
      "title" : "NOT COMPLETED at Washout Period (3 to 14 Days)",
      "code" : {
        "coding" : [
          {
            "system" : "https://fevir.net/resources/CodeSystem/179423",
            "code" : "results",
            "display" : "Results"
          }
        ],
        "text" : "Participant Flow Results"
      },
      "focus" : {
        "display" : "NOT COMPLETED at Washout Period (3 to 14 Days)"
      },
      "text" : {
        "status" : "empty",
        "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>"
      },
      "entry" : [
        {
          "reference" : "#NCT03421379-flow-milestone-2-Washout-Period--OPEN---3-to-1-FG000",
          "type" : "Evidence",
          "display" : "ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - NOT COMPLETED at Washout Period (3 to 14 Days)"
        },
        {
          "reference" : "#NCT03421379-flow-milestone-2-Washout-Period--OPEN---3-to-1-FG001",
          "type" : "Evidence",
          "display" : "ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - NOT COMPLETED at Washout Period (3 to 14 Days)"
        }
      ]
    },
    {
      "title" : "STARTED at Period 2",
      "code" : {
        "coding" : [
          {
            "system" : "https://fevir.net/resources/CodeSystem/179423",
            "code" : "results",
            "display" : "Results"
          }
        ],
        "text" : "Participant Flow Results"
      },
      "focus" : {
        "display" : "STARTED at Period 2"
      },
      "text" : {
        "status" : "empty",
        "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>"
      },
      "entry" : [
        {
          "reference" : "#NCT03421379-flow-milestone-0-Period-2-group-FG000",
          "type" : "Evidence",
          "display" : "ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - STARTED at Period 2"
        },
        {
          "reference" : "#NCT03421379-flow-milestone-0-Period-2-group-FG001",
          "type" : "Evidence",
          "display" : "ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - STARTED at Period 2"
        }
      ]
    },
    {
      "title" : "COMPLETED at Period 2",
      "code" : {
        "coding" : [
          {
            "system" : "https://fevir.net/resources/CodeSystem/179423",
            "code" : "results",
            "display" : "Results"
          }
        ],
        "text" : "Participant Flow Results"
      },
      "focus" : {
        "display" : "COMPLETED at Period 2"
      },
      "text" : {
        "status" : "empty",
        "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>"
      },
      "entry" : [
        {
          "reference" : "#NCT03421379-flow-milestone-1-Period-2-group-FG000",
          "type" : "Evidence",
          "display" : "ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - COMPLETED at Period 2"
        },
        {
          "reference" : "#NCT03421379-flow-milestone-1-Period-2-group-FG001",
          "type" : "Evidence",
          "display" : "ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - COMPLETED at Period 2"
        }
      ]
    },
    {
      "title" : "NOT COMPLETED at Period 2",
      "code" : {
        "coding" : [
          {
            "system" : "https://fevir.net/resources/CodeSystem/179423",
            "code" : "results",
            "display" : "Results"
          }
        ],
        "text" : "Participant Flow Results"
      },
      "focus" : {
        "display" : "NOT COMPLETED at Period 2"
      },
      "text" : {
        "status" : "empty",
        "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>"
      },
      "entry" : [
        {
          "reference" : "#NCT03421379-flow-milestone-2-Period-2-group-FG000",
          "type" : "Evidence",
          "display" : "ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - NOT COMPLETED at Period 2"
        },
        {
          "reference" : "#NCT03421379-flow-milestone-2-Period-2-group-FG001",
          "type" : "Evidence",
          "display" : "ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - NOT COMPLETED at Period 2"
        }
      ]
    }
  ]
}